Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC

"Orally available, small molecule, nonsteroidal potent and selective antagonist of the androgen receptor.~Cohort 1 dose: 120 mg QD Cohort 2 dose: 240 mg QD Cohort 3 dose: 180 mg QD"

"Abiraterone acetate is the prodrug of the active drug abiraterone. Once absorbed after oral administration, abiraterone acetate is rapidly converted to the active form, abiraterone.~Dose: 1000 mg QD"

"Taxane cytotoxic chemotherapy with demonstrated survival benefit in those with advanced prostate cancer.~Dose: 75 mg/m2 Q3W"

Dose: 5 mg BID